AccuLine's AI System Undergoes U.S. Clinical Trials for Heart Disease Detection
Sheba Medical Center and Tel Aviv Sourasky Medical Center-Ichilov have joined an international clinical trial to test an AI system developed by AccuLine, a medical technology startup based in Petah Tikva, Israel. The system, known as CORA, is designed to detect coronary artery disease noninvasively. The trial will involve approximately 2,000 patients across 20 medical centers, with most located in the United States. The aim is to validate the CORA system as part of its path toward FDA clearance. CORA analyzes data such as electrocardiograms, blood oxygen saturation, and respiration rates, along with clinical information and risk factors, to produce a coronary artery disease risk score in just four minutes. This method does not require physical exertion, radiation, or contrast agents. Previous studies in Israel have shown promising results, with a 94% sensitivity in identifying patients and a 99% negative predictive value in ruling out the disease. 
